QUOTE AND NEWS
Benzinga  11 hrs ago  Comment 
On CNBC's "Mad Money," Jim Cramer said he wouldn't sell Helmerich & Payne, Inc. (NYSE: HP) at its current price level. He wouldn't buy it either because he thinks it might trade to $48. He likes the stock in the long term. Cramer would sell...
FierceBiotech  Jun 22  Comment 
Eli Lilly has completed the expansion of its biotech facility in San Diego, California. The Big Pharma has more than doubled the size of the West Coast site and installed an automated, remote-controlled drug design and testing studio. 
Benzinga  Jun 15  Comment 
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares are trading lower by $12.00 (2.2 percent) at $464.84 in Thursday's session. The decline may be a delayed reaction to the company's 8-K filing released before Wednesday's open. Also on...
Motley Fool  Jun 14  Comment 
Here are a handful of things you probably haven't heard about one of the world's largest pharmaceutical companies.
MarketWatch  Jun 13  Comment 
A corporate dispute over a price-discount program for diabetes patients taking Eli Lilly & Co.’s insulin has resulted in an industry middleman’s exit from the deal — the latest sign of discord among players in a prescription-drug supply...
FierceBiotech  Jun 13  Comment 
With three positive phase 3 trials in hand, Eli Lilly heads for the FDA with migraine drug galcanezumab in pursuit of Amgen/Novartis.
MarketWatch  Jun 13  Comment 
Eli Lilly & Co. shares rose 1.5% in premarket trade Tuesday after the company said its pain drug with Pfizer Inc. has received fast track designation from the Food and Drug Administration, which is intended to hasten the development and approval...
FiercePharma  Jun 12  Comment 
Eli Lilly and Boehringer Ingelheim have reason to believe their SGLT2 inhibitor, Jardiance, may be able to improve outcomes for chronic kidney disease patients—so they’re putting the med to the test.




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki